These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
177 related items for PubMed ID: 31836686
1. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer. Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Krönke M, Herz M, Kropf S, Wester HJ, Weber WA, Eiber M. J Nucl Med; 2020 May; 61(5):702-709. PubMed ID: 31836686 [Abstract] [Full Text] [Related]
4. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. Knorr K, Oh SW, Krönke M, Wurzer A, D'Alessandria C, Herz M, Weber W, Wester HJ, Eiber M, Yusufi N, Nekolla S. EJNMMI Res; 2022 Feb 04; 12(1):8. PubMed ID: 35119557 [Abstract] [Full Text] [Related]
5. Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity. Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester HJ, Makowski M, Weber WA, Eiber M, Rauscher I. J Nucl Med; 2021 Aug 01; 62(8):1082-1088. PubMed ID: 33277394 [Abstract] [Full Text] [Related]
7. Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer. Piron S, De Man K, Van Laeken N, D'Asseler Y, Bacher K, Kersemans K, Ost P, Decaestecker K, Deseyne P, Fonteyne V, Lumen N, Achten E, Brans B, De Vos F. J Nucl Med; 2019 Dec 01; 60(12):1736-1742. PubMed ID: 31028165 [Abstract] [Full Text] [Related]
8. Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Cancer Biother Radiopharm; 2022 Apr 01; 37(3):205-213. PubMed ID: 34962139 [Abstract] [Full Text] [Related]
9. Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. Langbein T, Wang H, Rauscher I, Kroenke M, Knorr K, Wurzer A, Schwamborn K, Maurer T, Horn T, Haller B, Wester HJ, Eiber M. J Nucl Med; 2022 Sep 01; 63(9):1334-1342. PubMed ID: 34992154 [Abstract] [Full Text] [Related]
10. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, LIGHTHOUSE Study Group. Eur Urol; 2023 Oct 01; 84(4):361-370. PubMed ID: 37414702 [Abstract] [Full Text] [Related]
12. The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data. Langbein T, Wurzer A, Gafita A, Robertson A, Wang H, Arçay A, Herz M, Wester HJ, Weber WA, Eiber M. J Nucl Med; 2022 May 01; 63(5):742-745. PubMed ID: 34385338 [Abstract] [Full Text] [Related]
13. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. Yusufi N, Wurzer A, Herz M, D'Alessandria C, Feuerecker B, Weber W, Wester HJ, Nekolla S, Eiber M. J Nucl Med; 2021 Aug 01; 62(8):1106-1111. PubMed ID: 33443072 [Abstract] [Full Text] [Related]
20. Intra-individual dynamic comparison of 18F-PSMA-11 and 68Ga-PSMA-11 in LNCaP xenograft bearing mice. Piron S, Verhoeven J, Descamps B, Kersemans K, De Man K, Van Laeken N, Pieters L, Vral A, Vanhove C, De Vos F. Sci Rep; 2020 Dec 03; 10(1):21068. PubMed ID: 33273603 [Abstract] [Full Text] [Related] Page: [Next] [New Search]